Screening for Cognitive Dysfunctions in Patients with Combined Hashish and Tramadol Addiction
Relevance: A predictor of determining the quality of treatment is the patient’s cognitive abilities, which can be a useful screening tool for alerting potential problems during treatment. Purpose: screening of cognitive functions in patients with combined addiction to hashish and tramadol. Materials and methods: 129 male patients divided into 3 groups: group 1 (main) -41% of patients (n=53) with combined abuse of hashish and tramadol. Group 2 (control) – 34% of patients (n=44) with tramadol dependence. Group 3 (control) – 24.8% of patients (n=32) with dependence on cannabinoids. The level of reliability P <0.05 was taken as statistically significant changes. Results: The average score on the MOCA scale was 21.3±0.79 in patients of group 1, in group 2, 24.52±0.92 (P1-2 0.05). Patients with poly addiction and hashish dependence have violations of all medical processes – fixation, retention, and reproduction. Combined abuse of hashish and tramadol results in a synergy between the two psychoactive substances, which negatively affects cognitive functioning. Conclusion: The cannabinoid group is a major source of cognitive dysfunction. The MOSA test allows screening to the study of cognitive dysfunctions in general, regardless of individual cognitive domains, and to select the tactics of personalized drug and psychotherapeutic therapy.
